Tepotinib is a small molecule tyrosine kinase inhibitor that is used to treat adults with metastatic non-small cell lung cancer (NSCLC). It is specifically used for patients whose tumors have a certain type of mutation in the MET gene. Tepotinib works by blocking certain enzymes that help cancer cells to grow and divide. Common side effects include fatigue, nausea, diarrhea, and increased liver enzymes.
Tepotinib is a prescription medication sold under the brand name Tepmetko. It is a type of targeted therapy medication known as a kinase inhibitor. It is specifically designed to target a protein called MET, which is involved in cell growth and survival. Tepotinib works by blocking the MET protein from sending signals that tell cancer cells to grow and divide.
Tepotinib is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) that has a specific genetic mutation called MET exon 14 skipping. NSCLC is the most common type of lung cancer. Metastatic means that the cancer has spread to other parts of the body.